Clinical Trials

The purpose of this study is to monitor short term changes in bone microarchitecture, with the initiation of cross sex hormone therapy in transgender men and transgender women – during this time, there is a large flux in hormonal status.

The purpose of this study is to determine if cardiometabolic risk correlates with the estradiol (E) to testosterone (T) ratio or circulating concentrations, cross sex hormone duration or route, and to determine if changes in the E/T ratio are associated with changes in insulin sensitivity, body composition and adipose tissue fatty acid metabolism in transgender women.

The purpose of this study is to evaluate the longitudinal changes in lung volumes and spirometry parameters, after both masculinizing and feminizing hormone therapy in transgender and gender diverse (TGD) patients. Also, to determine the time of “gender adjustment” of PFT’s (pulmonary function test) normative values (PFTs results correlate most closely with patient’s gender than with their sex-assigned at birth) in response to gender-affirming hormone therapy in transgender and gender diverse (TGD) patients. Additionally, to implement a personalized approach to PFT interpretation using gender-appropriate normative values in transgender and gender diverse (TGD) patients, during the transition period and after ...

The purpose of this study is to determine how cystatin C, creatinine, and microalbuminuira change with gender affirming hormone therapy initiation. Blood draws and urine testing will be done at time 0, 3 months, and 6 months of hormone therapy. The results will  determine how to best interpret lab values in transgender individuals receiving gender affirming hormone therapy.